Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs
Dyspnea, Hypercapnia, Respiratory Insufficiency
About this trial
This is an interventional treatment trial for Dyspnea
Eligibility Criteria
Inclusion Criteria:
- Adults, 18 years or older
- Demonstrated severe dyspnea at baseline (Borg Rated Perceived Dyspnea [RPD] (scale 0-10) of 3 or higher)
- Severe baseline hypercarbia/hypercapnia of 50 mmHg or higher as measured by TcPCo2 or arterial or venous blood gas
Exclusion Criteria:
- Patient has unstable cardiovascular condition
- Significant unilateral or bilateral nasal occlusion
- Vigorous physical activity should not be performed within 2 hours of testing
- Inability to provide informed consent
- Pregnancy
- Known contraindication to perform steps of the protocol
- Absence of spontaneous respiration or known contraindication to HVNI
- Inability to use nasal cannula and HVNI therapy
- Agitation or uncooperativeness
- Determined by the clinician to be sufficiently unstable or unsuitable for this study
Sites / Locations
- VA Pittsburgh Healthcare System
- Erlanger Baroness Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Conventional Legacy Cannula Design (Control)
Cannula Design Test #1 (Randomized)
Cannula Design Test #2 (Randomized)
During this session, patients will be placed on HVNI therapy with an appropriately fitted Vapotherm conventional legacy cannula. Physiologic and ventilation parameters will be recorded.
During this session, patients will be placed on HVNI therapy with one of the next generation cannula designs. Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded.
During this session, patients will be placed on HVNI therapy with one of the next generation cannula designs. Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded.